Original Article

Acute subdural hematomas in shunted normal-pressure hydrocephalus patients – Management options and literature review: A case-based series

Assaf Berger², Shlomi Constantini¹,²,³, Zvi Ram²,³, Jonathan Roth¹,²,³

¹Departments of Pediatric Neurosurgery, Dana Children’s Hospital, ²Neurosurgery, Tel Aviv Medical Center, ³Tel Aviv University, Tel Aviv, Israel

E-mail: Assaf Berger - assaf.berger@gmail.com; Shlomi Constantini - sconsts@netvision.net.il; Zvi Ram - zviram@tlvmc.gov.il;
*Jonathan Roth - jonaroth@gmail.com
*Corresponding author

Received: 03 October 18    Accepted: 25 October 18    Published: 28 November 18

Abstract

Background: Ventriculoperitoneal shunting (VPS) is considered a risk factor for developing subdural hematomas (SDH). Treating cases of acute SDH (aSDH) in shunted normal-pressure hydrocephalus (NPH) patients can be challenging, and data in this field are scarce. We report our experience treating shunted NPH patients presenting with aSDH.

Methods: Eight patients, aged 73 ± 6 years, with a history of VPS for NPH, hospitalized because of aSDH were included in this study. We retrospectively analyzed data regarding patients’ clinical and radiological presentation, hospitalization course, the use of antithrombotics, and response to different treatment regimens.

Results: Four patients had pure aSDH, three had acute on chronic SDH, and one had subacute SDH. Patients presented with GCS 13–15 and various neurological signs, mainly confusion and unsteady gate. Two cases improved following resetting of their programmable shunt valve to its maximal pressure setting. Six cases improved after evacuation of the hematomas, five of them were operated a few days after initially resetting of the valve pressure. Three patients were discharged home, whereas five were referred to rehabilitation. Extended Glasgow Outcome Scale scores at discharge and during long-term follow-up were 5 and 7, respectively.

Conclusions: Treatment of patients with VPS for NPH, presenting with aSDH, may differ according to the neurological status, imaging, and clinical course. Treatment options include restricting shunt function, hematoma evacuation, or both.

Key Words: Acute subdural hematoma, hydrocephalus, shunt, treatment
INTRODUCTION

Normal-pressure hydrocephalus (NPH) is characterized by the Hakim–Adams triad, including gait disturbances, memory decline, and urinary incontinence. Ventriculoperitoneal shunts (VPS) are commonly used for treatment of NPH. Cerebrospinal fluid (CSF) shunting is considered a risk factor for subdural hematomas (SDH), which may develop among 2–17% of patients with CSF shunts. It is thought that the decrease in size of the drained ventricles results in stretching of bridging veins in the subdural space, making them prone for bleeding following even minor traumas. Additionally, a shunt can decrease the size of the ventricles, allowing more space for the developing hematoma while avoiding a potential “tamponade” effect, thus creating a more favorable milieu for bleeds to expand. Factors that have been associated with SDH in VPS patients include the valve-type of the shunt system and the use of antplatelet medications (APM) or anticoagulants. Lower valve settings predispose patients to overdrainage, increasing the risk for subdural hygromas and hematomas. In addition, patients with higher lumbar opening pressures before shunt insertion were found to have increased risk for SDH, probably resulting from a relatively stronger tendency toward overdrainage.

Managing cases of acute SDH (aSDH) in shunted NPH patients can be challenging because of the need for simultaneously addressing not only the hematoma itself but also the draining function of the shunt. The literature regarding handling of aSDH in patients with shunts is scarce and mainly based on case reports or small series. A recent paper described the treatment of 12 patients with ventriculoperitoneal and lumbo-peritoneal shunts who suffered from aSDH. Its main conclusion was that in cases that primarily underwent evacuation of the hematoma, treating the shunt by raising the valve pressure threshold or ligating it possibly reduced the rate of bleeding recurrence. On the other hand, patients initially treated only by intervening in their shunt systems (without treating the hematoma itself) occasionally needed a later evacuation of the hematoma.

As the data regarding this topic are limited, we chose to present our experience in treating NPH patients with VPS, who suffered from aSDH. An analysis and comparison of the different treatment options are discussed.

MATERIALS AND METHODS

We retrospectively reviewed the hospital records of adult (>18 years old) NPH patients with VPS, who suffered from aSDH, that were hospitalized in the Department of Neurosurgery at the Tel Aviv Medical Center between the years 2010 and 2016. We included only primary NPH patients. Patients with acute on chronic or subacute bleeds were included too.

We did not include cases who presented with purely chronic bleeds or hypodense subdural effusions. Patients with intraparenchymal hematomas were also not included.

1. Eight patients with acute, acute on chronic, or subacute SDH were identified and analyzed for the following details: patients’ age, gender, cause of hydrocephalus, and use of APM or anticoagulant medications prior to injury

2. Circumstances and timing of head injury, duration between symptom onset and admission, Glasgow Coma Scale (GCS), and neurological deficits on admission and during hospitalization were documented. The maximal width of the hematomas and midline shift (MLS) were measured on admission and during follow-up

3. Treatments and their timing during the hospitalization were recorded, including changing of the shunt’s valve pressure setting, shunt ligation or externalization, the addition of shunt assist devices, and surgical procedures for evacuation of the hematomas

4. Outcome included discharge destination (home, rehabilitation, or nursing care) and Extended Glasgow Outcome Scale (GOSE) at discharge and follow-up. We also recorded the development of recurrent NPH-related symptoms, the need for additional shunt related surgeries, and the need for additional hematoma related surgeries.

The study was performed following an Institutional Review Board approval (0705-16-TLV) and in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki. For this type of retrospective study, informed consent was waived. The authors have no potential conflicts of interest to disclose. This study did not receive any specific grants from funding agencies in the public, commercial, or not-for-public sectors.

Statistics
This is an observational study, focusing on a small patients group; thus, no statistical analyses were done. Data are presented in a descriptive manner, and numerical data are presented as mean ± standard deviation.

RESULTS

Patient background
Over a period of 7 years (2010–2016), 210 patients received a VPS for the diagnosis of NPH at our center. During the same period, eight of these patients were hospitalized with acute or subacute SDH. The average
age at presentation was 73 ± 6 years, ranging from 64 to 85 years of age. All patients were male.

Five patients were pretreated with APM, including four with aspirin and one with clopidogrel. APM were discontinued before shunt placement for at least 10 days and resumed within 1 month after discharge. One additional patient who had a history of lymphoma and was treated with enoxaparin also suffered from thrombocytopenia during the traumatic event

Table 1: Individual patient’s data

| Age  | Gender | Valve-type and pressure setting | Hemorrhage type, side | Hematoma width and MLS (mm) at presentation | Clinical presentation: GCS, neurological condition | Use of anticoagulation/ APM: treatment with procoagulant factors or PLTs | Intervention (days from admission) | Discharge destination and GOSE |
|------|--------|---------------------------------|-----------------------|------------------------------------------|-------------------------------------------------|----------------------------------------------------------------|----------------------------------|---------------------------------|
| 85, M|        | Medos 150 mmH,0                 | ASDH, Rt              | 3; 0                                      | 13, Confusion                                    | Clopidogrel; PLT                                             | Day 1: resetting valve pressure to 200 mmH,0 | Rehabilitation, GOSE 5          |
| 64, M|        | Medos 180 mmH,0                 | Acute on CSDH, Rt     | 13; 6                                     | 15, Lt arm pronation                            | No; no                                                      | Day 1: resetting valve pressure to 200 mmH,0 | Home, GOSE 7                    |
| 74, M|        | Medos 200 mmH,0                 | Acute on CSDH, Lt     | 30; 13                                    | 14, Confusion                                    | No; no                                                      | Day 1: burr hole, shunt ligation       | Home, GOSE 7                    |
| 71, M|        | Medos 150 mmH,0                 | ASDH, Rt              | 15; 5                                     | 15, Lt facialis and hemiparesis                 | Clexane, thrombocytopenia; PLT                              | Day 1: resetting valve pressure to 200 mmH,0 | Rehabilitation, GOSE 5          |
| 68, M|        | Strata 1                        | ASDH, Lt              | 13; 4                                     | 15, Intact                                       | Aspirin; PLT                                                | Day 1: resetting valve pressure to 2.5 mmH,0 | Rehabilitation, GOSE 4          |
| 76, M|        | Medos 140 mmH,0                 | Subacute SDH, Lt > Rt | Lt: 28                                    | 14, Confusion                                    | Aspirin; PLT                                                | Day 1: resetting valve pressure to 200 mmH,0 | Rehabilitation, GOSE 4          |
| 75, M|        | Medos 150 mmH,0                 | ASDH, Lt              | 24; 2                                     | 15, Unsteadiness                                 | Aspirin; no                                                 | Day 1: resetting valve pressure to 200 mmH,0 | Home, GOSE 5                    |
| 73, M|        | Medos 80 mmH,0                  | Acute on CSDH, Lt     | 14; 7                                     | 13, Confusion                                    | Aspirin; no                                                 | Day 1: resetting valve pressure to 200 mmH,0 | Rehabilitation, GOSE 5          |

M=Male, Rt=Right, Lt=Left, NPH=Normal-pressure hydrocephalus, CSDH=Chronic subdural hematoma, aSDH=Acute subdural hematoma, MLS=Midline shift, APM=Antiplatelet medications, PLT=Platelets, GCS=Glasgow Coma Scale, GOSE=Extended Glasgow Outcome Scale.

Patient history and baseline imaging

All patients had VPS inserted for 14 ± 15 months (range 3–48) prior to their current presentation. Two types of shunt valves were used: Medos programmable valves with siphonguard (Codman Inc.) programed to 80–200 mmH,0 (seven cases) and Strata valve (Medtronic Inc.) programed at 1 (one case). All shunts were located in the right lateral ventricle and were placed via a parieto-occipital entry [Table 1].

Baseline imaging, performed 5 months (range 2–11) prior to the current admission, showed no subdural bleeding. The indication for these CT scans was routine surveillance of shunted NPH patients to document radiological signs of overdrainage. Case 3 had bilateral subdural hygromas and had insertion of shunt-assisted device (SAD) because of overdrainage syndrome 2 months prior to developing acute on chronic SDH. This patient did not have a new CT scan following the addition of the SAD and prior to admission with the bleed. The other seven cases had no evidence for subdural collections prior to their current admission.

Presentation on admission

Four patients had an aSDH following a fall on the day of admission. Three patients had an acute on chronic SDH, and one had subacute SDH, most of which were associated with recurrent falls over a period of several weeks to months with an acute deterioration just before their admission. GCS on admission ranged from 13 to 15 and the examination was mainly significant for non-focal signs, such as confusion (4) and unsteady gait (1), but also hemiparesis (2) and facial palsy (1).

Hematomas were located on the left (contralateral to the shunt) in five patients (one of which had also a small right bleed). Maximal hematoma width and MLS were 30 and 13 mm, respectively, both of which occurred in an NPH patient with acute on chronic SDH. In cases of left-sided (contralateral) SDH, the size of hematoma and MLS on admission was 22 ± 8 and 7 ± 4 mm, respectively, as compared with 10 ± 6 and 4 ± 3 mm on the right ipsilateral side [Table 1].
Management of clotting disturbances

Three of the five patients who were using APM, as well as one patient with lymphoma and thrombocytopenia that was also using enoxaparin, were given platelets on admission. In all cases, APM and anticoagulants were stopped on admission. Eventually, APM were discontinued permanently in two of the five previously treated patients, whereas it was recommenced in three of them. Enoxaparin treatment was recommenced before discharge for the prophylaxis of venous thrombosis in the case of lymphoma and thrombocytopenia [Table 1].

Management

There were no urgent craniotomies for aSDH. Burr hole (BH) evacuation of SDH was performed in six cases on days 1–23 of admission. BH was performed in all five cases in which the hematoma was contralateral to the shunt, as compared with only one of three cases, in whom the hematoma was ipsilateral to the shunt.

Patients were treated along three different pathways: increasing shunt valve pressure settings without evacuation of the hematoma (two cases), early BH with concurrent shunt adjustments on day of hospitalization (one case), and shunt adjustments followed by late BH (five cases).

Increasing shunt valve pressure setting

Two cases (1 and 4) improved following resetting shunt valves to their maximal pressures. They later developed recurrent NPH symptoms and had their valve pressures decreased. Their MLS and hematoma thickness on admission were no more than 5 and 15 mm, respectively [Table 1].

Early BH with concurrent shunt adjustments

One case (3) with acute on chronic SDH underwent a BH evacuation on the day of admission. This patient suffered from confusion and had a large hematoma of 30 mm and MLS of 13 mm. He showed substantial clinical improvement following BH and shunt ligation. One month later, he developed recurrent NPH-like symptoms necessitating reopening of the shunt system, with no need for any further interventions during a follow-up period of almost 2 years [Table 1].

Shunt adjustments followed by late BH

Five cases (2, 5, 6, 7, 8) had their shunt valve pressures adjusted on admission but underwent BH between days 5 and 23 of admission. The initial size of the hematoma and MLS was relatively large, ranging 13–28 and 2–9 mm, respectively. Three patients had increase in either the hematoma size or MLS before the BH. Three patients had clinical deterioration, whereas two had no improvement under conservative treatment and thus had the hematoma drained. All patients improved upon discharge. Shunt valve pressure settings had to be later decreased in three cases because of recurrent NPH symptoms [Table 1].

Outcome

Three patients were discharged home and five were referred to rehabilitation. No residual or recurrent hematoma was documented in any of the cases over a median of 10 months (range: 1 month–4 years). All patients showed improvement in their clinical outcome compared to that on admission. GOSE on discharge was 5 and improved to 7 after a few months of follow-up [Table 1].

DISCUSSION

To our knowledge, this article is one of the first to describe management options in shunted NPH patients presenting with aSDH or subacute SDH. In this article, we did not explore or analyze risk factors associated with bleed occurrence, but rather the actual treatment options. The typical patient would be an adult (usually an elderly), often taking anticoagulants or APM, presenting in the context of falls (with or without a clear head injury event), with a nonspecific neurological decline. Patients presenting with mass-effect-related symptoms – such as declined consciousness or focal neurological signs, necessitate an urgent hematoma evacuation with a craniotomy. However, smaller hematomas, or those with no mass effect-related symptoms, may be followed or treated with restriction of the shunt function. Some of these patients may eventually undergo hematoma evacuation at a later stage – possibly with a BH. Regardless to the treatment of the hematoma, restriction of the shunt’s function was part of the treatment for all patients. Thus, we recommend restriction of the shunt function by increasing the shunt pressure settings. Whether to externalize the shunt and temporarily close it, ligate the shunt, or drain the hematoma, and the timing of such a procedure, should be based on clinical and radiological findings at presentation and during follow-up.

Reviewing the literature, there are limited data regarding the actual treatment of VPS patients presenting with aSDH, which is not associated with overdrainage. Yet, our decision-making for each individual case was based on previous reports and their relevance to the clinical scenarios.\(^5,8\) Hoya et al. described 2 cases out of a series of 12 that improved after increasing shunt valve pressure settings, with both being considered as having relatively smaller hematomas. It is speculated that raising the valve pressure setting elevates intracranial pressure (ICP) just enough to prevent hematoma expansion but not too severe to induce high ICP signs.\(^10\) The assumption is that in cases of communicating hydrocephalus as in NPH patients, decreasing ventricular shunt drainage would force CSF to spread into alternative routes,
CONCLUSIONS

When treating aSDH in NPH-shunted patients, one should take into account the combined effects of both the hematoma mass effect and the CSF drainage by the shunt. Increasing the shunt valve pressure setting might be effective for some; however, these patients should be followed carefully as most will also require evacuation of their hematomas. Whether and when to evacuate the bleed are based on clinical and radiological findings and dynamics. Last, long-term follow-up is important, as some patients may need to readjust their shunt because of the recurrence of NPH-related symptoms.

Acknowledgements

None.

Ethical approval

The study was performed following an Institutional Review Board (IRB) approval (0705-16-TLV) and in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Declaration of patient consent

For this type of retrospective study, informed consent was waived.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Baharoglu MI, Cordonnier C, Al-Shahi Salman R, de Gans K, Koopman MM, Brand A, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): A randomised, open-label, phase 3 trial. Lancet (London, England) 2016;387:2605-13.
2. Birkeland P, Lauritsen J, Poulsen FR. Aspirin is associated with an increased risk of subdural hematoma in normal-pressure hydrocephalus patients following shunt implantation. J Neurosurg 2015;123:423-6.
3. Birkeland P, Lauritsen J, Poulsen FR. Subdural haematoma complicating shunting for normal pressure hydrocephalus in the setting of concomitant antiplatelet medication-a report of 11 cases. Br J Neurosurg 2016;30:567-70.
4. Brean A, Eide PK. Prevalence of probable idiopathic normal pressure hydrocephalus in a Norwegian population. Acta Neurol Scand 2008;118:48-53.
5. Brown SR, Gottfried ON, Ragert BT, Kestle JR. Failure of cerebrospinal fluid shunts: Part II: Overdrainage, loculation, and abdominal complications. Pediatr Neurol 2006;34:171-6.
6. Frontera JA, Lewin JJ 3rd, Rabinstein AA, Asikpu IP, Alexandrov AW, Cook AM, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: Executive summary. A statement for healthcare professionals from the Neurocritical Care Society and the Society of Critical Care Medicine. Crit Care Med 2016;44:2251-7.
7. Goodwin CR, Kharkar S, Wang P, Pujari S, Rigamonti D, Williams MA. Evaluation and treatment of patients with suspected normal pressure hydrocephalus on long-term warfarin anticoagulation therapy. Neurosurgery 2007;60:497-501; discussion 502.
8. Hayes J, Roguski M, Riesenburger RJ. Rapid resolution of an acute subdural hematoma by increasing the shunt valve pressure in a 63-year-old man with
normal-pressure hydrocephalus with a ventriculoperitoneal shunt: A case report and literature review. J Med Case Rep 2012;6:393.

9. Hoh BL, Kleinhenz DT, Chi YY, Mocco J, Barker FG 2nd. Incidence of ventricular shunt placement for hydrocephalus with clipping versus coiling for ruptured and unruptured cerebral aneurysms in the Nationwide Inpatient Sample database: 2002 to 2007. World Neurosurg 2011;76:548-54.

10. Hoya K, Tanaka Y, Uchida T, Takano I, Nagaishi M, Kowata K, et al. Treatment of traumatic acute subdural hematoma in adult hydrocephalus patients with cerebrospinal fluid shunt. Clin Neurol Neurosurg 2012;114:211-6.

11. Kamiryo T, Hamada J, Fuwa I, Ushio Y. Acute subdural hematoma after lumboperitoneal shunt placement in patients with normal pressure hydrocephalus. Neurol Med Chir (Tokyo) 2003;43:197-200.

12. Khan QU, Wharen RE, Grewal SS, Thomas CS, Deen HG Jr, Reimer R, et al. Overdrainage shunt complications in idiopathic normal-pressure hydrocephalus and lumbar puncture opening pressure. J Neurosurg 2013;119:1498-1502.

13. Mahaney KB, Chalouhi N, Viljoen S, Smietana J, Kung DK, Jabbour P, et al. Risk of hemorrhagic complication associated with ventriculoperitoneal shunt placement in aneurysmal subarachnoid hemorrhage patients on dual antiplatelet therapy. J Neurosurg 2013;119:937-42.

14. O’Kelly CJ, Kulkarni AV, Austin PC, Urbach D, Wallace MC. Shunt-dependent hydrocephalus after aneurysmal subarachnoid hemorrhage: Incidence, predictors, and revision rates. J Neurosurg 2009;111:1029-35.

15. Sundstrom N, Lagebrant M, Blund A, Koskinen LD, Malm J. Subdural hematomas in 1846 patients with shunted idiopathic normal pressure hydrocephalus: Treatment and long-term survival. J Neurosurg 2018;129:797-804.

16. Weir J, Steyerberg EW, Butcher I, Lu J, Lingsma HF, McHugh GS, et al. Does the extended Glasgow outcome scale add value to the conventional Glasgow outcome scale? J Neurotrauma 2012;29:53-8.

17. Yamada SM, Tomia Y, Muraliini H, Nakane M. Management for traumatic chronic subdural hematoma patients with well-controlled shunt system for hydrocephalus. Clin Case Rep 2015;3:548-50.